• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Veradigm Inc.

    9/3/24 9:10:52 AM ET
    $MDRX
    EDP Services
    Technology
    Get the next $MDRX alert in real time by email
    8-K
    NONE false 0001124804 0001124804 2024-08-27 2024-08-27

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 27, 2024

     

     

    VERADIGM INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-35547   36-4392754

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    222 Merchandise Mart  
    Chicago, Illinois   60654
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 800 334-8534

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   MDRX   N/A (OTC Expert Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 1.02 Termination of a Material Definitive Agreement.

    As previously reported, on April 29, 2022, Veradigm Inc. (the “Company”) and Veradigm LLC, a wholly-owned subsidiary of the Company (Veradigm LLC, together with the Company, the “Borrower”), entered into that certain Third Amended and Restated Credit Agreement (as amended from time to time prior to the date hereof, the “Credit Agreement”), with the lenders party thereto (the “Lenders”) and JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”). Pursuant to the Credit Agreement, the Lenders provided for a revolving credit facility available to the Borrower, and as of August 27, 2024, there was no balance outstanding under such revolving credit facility.

    On August 27, 2024, the Company provided notice to the Agent to terminate the Credit Agreement and all Commitments (as defined in the Credit Agreement) thereunder effective as of August 30, 2024.

    As of August 30, 2024, the Company has satisfied and discharged all obligations under the Credit Agreement, except for obligations expressly contemplated to survive payment of the obligations thereunder. The Company incurred no termination penalties in connection with the termination of the Credit Agreement. The Company terminated the Credit Agreement in order to avoid the occurrence of an Event of Default (as defined in the Credit Agreement) as a result of the Company’s failure to timely furnish the required financial statements in accordance with the terms of the Credit Agreement. Given the costs associated with the unused facility and the sufficiency of the cash and liquidity available to the Company to support its continuing operations, Company management believes that it is both cost-efficient and in the overall best interests of the Company and its stockholders to terminate the Credit Agreement at this time.

    Disclaimer and Forward-Looking Statement Information

    This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding the Company’s beliefs regarding the termination of the Credit Agreement. These forward-looking statements are based on the current beliefs and expectations of the Company’s management with respect to future events, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plan,” “predicts,” “will,” “would,” “could,” “continue,” “can,” “may,” “look forward,” “aim,” “hopes,” “seek” and similar terms, although not all forward-looking statements contain such words or expressions. Actual results could differ significantly from those set forth in the forward-looking statements.

    Important factors that may cause actual results to differ materially from those in the forward-looking statements include, among others, factors contained in the “Risk Factors” section and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission from time to time, including, but not limited to, its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q and its Current Report on Form 8-K filed on January 10, 2024. The Company does not undertake to update any forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes over time, except as required by law


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          VERADIGM INC.
    Date: September 3, 2024     By:  

    /s/ Eric Jacobson

          Eric Jacobson
          Senior Vice President, Deputy General Counsel and Corporate Secretary
    Get the next $MDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDRX

    DatePrice TargetRatingAnalyst
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    1/3/2024$11.00Equal Weight
    Barclays
    7/6/2023Buy → Hold
    Argus
    4/12/2023$13.00Equal-Weight
    Stephens
    2/1/2023$17.00 → $18.50Overweight → Neutral
    Piper Sandler
    12/7/2022$26.00Hold → Buy
    Argus
    11/9/2022$22.00 → $23.00Neutral → Buy
    Goldman
    11/4/2022$17.00Overweight
    Piper Sandler
    More analyst ratings

    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4) (Amendment)

      4/A - Veradigm Inc. (0001124804) (Issuer)

      3/15/24 5:16:45 PM ET
      $MDRX
      EDP Services
      Technology
    • Stonehill Capital Management Llc bought $66,001,500 worth of shares (10,222,875 units at $6.46) (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      3/4/24 9:50:46 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    SEC Filings

    See more
    • SEC Form 8-K filed by Veradigm Inc.

      8-K - Veradigm Inc. (0001124804) (Filer)

      5/22/25 6:04:43 AM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form NT 10-Q filed by Veradigm Inc.

      NT 10-Q - Veradigm Inc. (0001124804) (Filer)

      5/12/25 4:40:37 PM ET
      $MDRX
      EDP Services
      Technology
    • SEC Form SCHEDULE 13G filed by Veradigm Inc.

      SCHEDULE 13G - Veradigm Inc. (0001124804) (Subject)

      5/12/25 2:19:02 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief HR Officer Hammond Lisa was granted 58,140 shares, increasing direct ownership by 50% to 174,175 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      6/5/25 5:28:24 PM ET
      $MDRX
      EDP Services
      Technology
    • SVP General Counsel Vakharia Tejal was granted 69,768 shares, increasing direct ownership by 22% to 387,476 units (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      6/5/25 5:22:40 PM ET
      $MDRX
      EDP Services
      Technology
    • Director Sacks Jonathan S was granted 46,512 shares and converted options into 8,696 shares (SEC Form 4)

      4 - Veradigm Inc. (0001124804) (Issuer)

      6/3/25 9:28:21 PM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare

      Podcast supports company's mission to transform health insightfully, offering expert perspectives and proven strategies to help improve outcomes and reduce costs Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, a

      6/5/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Recognized with KLAS 2025 Points of Light Award for Optimizing Value-Based Care

      Delivering insights at the point-of-care to close quality care gaps resulted in a time savings of 20 hours per week and improved patient care for Metroplex Medical Centres Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, along with Metroplex Medical Centres and one of the largest healthcare payer organizations in the country, received a 2025 KLAS Points of Light Award. The case study titled, "Optimizing Value-Based Care by Delivering Insights at the Point of Care," showcased how Veradigm and the payer integrated alerts into Metroplex Medical Centres' electronic health record (EHR) to help improve clinical decision support, reduce healthcare provider bur

      5/20/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Advances GLP-1 Real-World Evidence Generation with AI-Driven EHR Data Curation

      AI-powered insights from the Veradigm Network reveal real-world GLP-1 outcomes hidden in EHR data Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of real-world evidence (RWE) for GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide. By applying AI to electronic health record (EHR) deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights—such as side effects, discontinuation reasons, and social determinants of health (SDoH)—that traditionally required intensive manual curation. GLP-1 therapi

      5/12/25 8:01:00 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Veradigm downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously

      3/19/24 7:50:39 AM ET
      $MDRX
      EDP Services
      Technology
    • Barclays initiated coverage on Veradigm with a new price target

      Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00

      1/3/24 8:00:02 AM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm downgraded by Argus

      Argus downgraded Veradigm from Buy to Hold

      7/6/23 9:00:49 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

      Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

      3/18/25 4:47:00 PM ET
      $CMBM
      $DOMO
      $EVH
      $MDRX
      Radio And Television Broadcasting And Communications Equipment
      Technology
      Computer Software: Prepackaged Software
      Other Consumer Services
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Sprinklr Set to Join S&P SmallCap 600

      NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea

      2/28/24 5:50:00 PM ET
      $CXM
      $MDRX
      $SPGI
      Computer Software: Prepackaged Software
      Technology
      EDP Services
      Finance: Consumer Services

    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Veradigm Inc.

      SC 13G - Veradigm Inc. (0001124804) (Subject)

      11/14/24 4:05:58 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/14/24 1:11:13 PM ET
      $MDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

      SC 13G/A - Veradigm Inc. (0001124804) (Subject)

      11/8/24 10:29:29 AM ET
      $MDRX
      EDP Services
      Technology

    $MDRX
    Financials

    Live finance-specific insights

    See more
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Veradigm to Release Financial Update March 18th and Host Investor Call March 19th

      Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a financial update after the close of regular stock market hours on March 18, 2025. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on March 19, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Tuesday, March 18, 2025. The announcement will also be available at the Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations we

      3/13/25 9:57:00 PM ET
      $MDRX
      EDP Services
      Technology
    • Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review

      Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti

      1/30/25 4:02:00 PM ET
      $MDRX
      EDP Services
      Technology